Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
A group of researchers from the annual meeting of the American Academy of Orthopedic Surgeons (AAOS) "analyzed the data and...
Read Full NewsThe World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being...
Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.
The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
1.
EVP Beats Cisplatin for Resectable MIBC
2.
Could CT scans be fueling a future rise in cancer cases, as a new study suggests?
3.
Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment
4.
Next-Generation KRAS G12C Inhibitor Shows 'Robust' Efficacy in Advanced Lung Cancer
5.
Cancer Warnings on Alcohol? Surge in GI Illnesses; Swab Detects Kids' Asthma Type
1.
Seeing the Unseen: Examining Chancroid Through Images
2.
Beyond Immunotherapy: Emerging Novel Treatments for Small Cell Lung Cancer
3.
Revolutionizing Cancer Care: The Promise of Early Detection and Biomarkers
4.
Giant Sebaceous Cyst of the Scalp Mimicking a Soft Tissue Tumor: A Case Study
5.
Refractory Iron Deficiency Anemia in a Young Adult: Diagnostic Challenges
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
2.
Efficient Management of First line ALK-rearranged NSCLC - Part III
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
4.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
5.
Navigating the Complexities of Ph Negative ALL - Part XV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge